Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Early Findings from the Multicenter RAPID Consortium on Papillary Craniopharyngiomas.

Journal of neurological surgery. Part B, Skull base·2026

Same author

A modular and flexible pipeline for intraoperative electrode reconstruction and localization in patients with brain lesions.

Frontiers in neural circuits·2026

Same author

IDH1-Associated m6A Methylation Is Linked to Transcriptomic Heterogeneity in Glioma.

Cancers·2026

Same author

Safety and Efficacy of Expedited Discharge Protocols After Endoscopic Endonasal Pituitary Surgery: A Single-Center Cohort Study.

Neurosurgery·2026

Same author

Frailty and postoperative outcomes following craniopharyngioma resection: a multicenter Registry for Adenomas of the Pituitary and Related Disorders analysis.

Neurosurgical focus·2026

Same author

A Century of Transsphenoidal Pituitary Surgery: Bibliometric Insights Into Global Research Trends and the Evolution of Evidence.

Operative neurosurgery (Hagerstown, Md.)·2026

Search research articles

Related Experiment Video

Updated: Apr 16, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Immunotherapy for malignant glioma.

Carter M Suryadevara¹, Terence Verla², Luis Sanchez-Perez²

¹Duke Brain Tumor Immunotherapy Program, Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA ; Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA ; The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC 27710, USA.

Surgical Neurology International

|February 28, 2015

Summary

Chimeric antigen receptor (CAR) T-cell therapy offers a promising immunotherapy for malignant gliomas (MG), including glioblastoma (GBM). This approach aims to specifically target brain tumors while minimizing damage to healthy tissue.

Keywords:

Adoptive cell transfer brain tumors central nervous system glioma immunotherapy

More Related Videos

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

Related Experiment Videos

Last Updated: Apr 16, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

Area of Science:

Neuro-oncology
Immunology
Cancer Therapy

Background:

Malignant gliomas (MG), particularly glioblastoma (GBM), are aggressive brain tumors with poor prognoses.
Current treatments like surgery, radiation, and chemotherapy have significant toxicities and limited efficacy.
There is a critical need for targeted therapies to treat central nervous system (CNS) tumors effectively.

Purpose of the Study:

To review emerging immunotherapeutic platforms for malignant glioma treatment.
To focus on the development and clinical application of chimeric antigen receptor (CAR) T-cell therapy for glioblastoma (GBM).

Main Methods:

Review of scientific literature on immunotherapy for malignant gliomas.
Focus on T-cell engineering and CAR T-cell platform evolution.
Analysis of CAR T-cell strategies specifically for glioblastoma (GBM).

Main Results:

Immunotherapy, specifically CAR T-cell therapy, shows potential for treating brain tumors.
Modern CAR T-cell constructs have improved designs and are being translated to the clinic for brain tumors.
CAR T-cell therapy aims to redirect a patient's T-cells to target and eliminate tumor cells.

Conclusions:

CAR T-cell therapy represents a promising investigational approach for malignant gliomas.
This immunotherapy strategy has the potential to overcome limitations of conventional treatments.
Further development and clinical application of CAR T-cells are crucial for advancing brain tumor treatment.